HBV and HCV Seroprevalence in Hospital Admissions for Thalassemia Major in Bengbu, China
HBV and HCV Seroprevalence in Hospital Admissions for Thalassemia Major in Bengbu, China
Jun Zhang1*, Xiaocao Xu2 and Min Cao2
ABSTRACT
Patients with thalassemia major are exposed to a wide range of blood transition viruses that among them hepatitis B and C viruses are in high significance. This study investigates the seroprevalence of HBV and HCV in hospital admissions for thalassemia major in Bengbu, China. This study is a cross-sectional study in which information was extracted and collected from patients’ records, including gender, age, number of blood transfusions per year, HBs-Ag, HCV-Ab and Anti-HBs. The study included 630 thalassemia major patients who received regular blood transfusions at a hospital in Bengbu, China. We found that out of 630 patients of the study, there were three HBs-Ag positive, so the prevalence of HBV in this study is 0.5%. The prevalence of HCV-Ab positive was 7.1 and these individuals had a significantly older mean age than those with HCV-Ab negative. In 89.8% of patients the HBs-Ab titer was more than 10. Due to the progress of screening and selection of blood donors the prevalence of HBV infection in high-risk patients has sharply decreased in recent years. Vaccination is one of the most important protective factors in this group of the population. Therefore, administration of a reminder dose based on antibody titer is recommended in these individuals.
To share on other social networks, click on any share button. What are these?
